Royalty Report: Drugs, Cannabis, Pain – Collection: 293157

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cannabis
  • Pain
  • Delivery
  • Therapeutic
  • Technical Know How
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 293157

License Grant
The Israeli Licensor, the technology transfer company of the University, granted Licensee a worldwide exclusive license to develop and commercialize certain patents, know-how and research results (collectively, the 2018 Hebrew Licensed Technology), in order to develop, manufacture, market, distribute or sell products, all within the use of the 2018 Hebrew Licensed Technology.
License Property
Licensor will undertake research and to synthesize chemical compounds that will be used by Licensee, through additional research at two Universities, to develop orally active analgesic and anti-inflammatory medications. Compounds will be shipped from University to Oxford for use in pre-clinical studies to establish efficacy in pain and inflammation.
Field of Use
This agreement pertains to the drug industry for the treatment of any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the 2018 Field).

The license is to develop and commercialize certain patents in order to develop, manufacture, market, distribute, sell, repair and refurbish products, all within the use of the 2019 Hebrew Licensed Technology for (i) Cannabinoid phenolate metal salts, including mono, di and trivalent metals such as Li, Na, K, Ca, Mg, Zn, Fe and Al and their mixtures with native or synthetic cannabinoids, their pharmaceutical formulations, including for oral and topical administration; and (ii) pharmaceutical formulations, for the administration of cannabinoid chemical derivatives, including any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the “2019 Field”).

IPSCIO Record ID: 255048

License Grant
The Israeli Licensee entered into an exclusive, worldwide, sublicensable, royalty-bearing license with the Israeli Licensor, the technology transfer company of the University, for license to make commercial use of the licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell Products, all within the field of cannabinoid technology and delivery.
License Property
Cannabinoid technology.
Field of Use
The Israeli Licensee business is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals and advanced drug delivery projects.

IPSCIO Record ID: 372460

License Grant
Licensor of Japan grants to Licensee of the United Kingdom under the Collaboration IP, the nonexclusive right to use the same in any way whatsoever for the purpose of the Research Collaboration including to research, make, have made and use  Research Compounds for the purposes necessary to perform its obligations and exercise its rights under the Research Plan.

This agreement is for the research and early stage development of pharmaceutical preparations based upon Research Compounds (as defined below) for the treatment of CNS and cancer indications.

License Property
Licensor has intellectual property of botanical extracts from chemovars of Cannabis sativa for the treatment of CNS and cancer indications.

Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.

Botanical Drug Candidate or BDC shall mean
—  any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
—  a combination of two or more Phytocannabinoid extracts described above containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and,
—  any biological or chemical modification of the Phytocannabinoids in above including any metabolite or degradant.

Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid) or outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).

Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).

Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabiooid but which has been developed with information resulting from the Research Collaboration and for which one or more patent.

Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.

Field of Use
The  fields of use are neuropsychopharmacology, with special reference to schizophrenia; cannabinoid/opioid analgesic combinations; and, oncology.

The Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.